Wang Xiaoyin, Fisher Patrick W, Xi Lei, Kukreja Rakesh C
Division of Cardiology, Department of Internal Medicine, Box 980204, Virginia Commonwealth University, 1101 East Mashall Street, Room 7-046, Richmond, VA 23298-0204, USA.
J Mol Cell Cardiol. 2008 Jan;44(1):105-13. doi: 10.1016/j.yjmcc.2007.10.006. Epub 2007 Oct 16.
Sildenafil (Viagra), a phosphodiesterase type-5 inhibitor used in treatment of male erectile dysfunction and pulmonary hypertension can induce cardioprotection through opening of mitochondrial ATP-sensitive K(+) channels (mitoK(ATP)). Recent studies suggest that activation of mitochondrial Ca(2+)-activated K(+) channels (mitoK(Ca)) also has anti-ischemic effects. However, the relative role of mitoK(Ca) and mitoK(ATP) in sildenafil-induced cardioprotection remains unknown. In the present study, adult male ICR mice were pretreated with sildenafil (0.71 mg/kg, i.p.) 24 h prior to 20 min of global ischemia followed by 30 min of reperfusion in Langendorff mode. Paxilline (blocker of K(Ca)) or 5-hydroxydecanoic acid (5-HD; blocker of mitoK(ATP)) was administered either 30 min before sildenafil or 10 min prior to ischemia. Treatment with sildenafil reduced infarct size, which was abolished by either paxilline or 5-HD. Furthermore, in vivo gene knockdown of beta1 subunit of K(Ca) (K(Ca)-beta1) using small interfering RNA (siRNA) administered 48 h before sildenafil injection blocked the infarct limiting effect of sildenafil. The protective effect of sildenafil was preserved in mice treated with non-target siRNA. Western blots demonstrated selective protein expression of K(Ca)-beta1 in cardiac mitochondria and the gene knockdown effect of siRNA on K(Ca)-beta1. The level of K(Ca)-beta1 protein was not upregulated following treatment with sildenafil. We conclude that both mitoK(Ca) and mitoK(ATP) play a critical role in triggering and mediating sildenafil-induced delayed cardioprotection. The results suggest that activation of mitoK(Ca) and mitoK(ATP) are crucial for maintaining mitochondrial homeostasis and reducing cell death in sildenafil-induced preconditioning against ischemia-reperfusion injury.
西地那非(伟哥)是一种磷酸二酯酶5型抑制剂,用于治疗男性勃起功能障碍和肺动脉高压,它可通过开放线粒体ATP敏感性钾通道(mitoK(ATP))诱导心脏保护作用。最近的研究表明,线粒体钙激活钾通道(mitoK(Ca))的激活也具有抗缺血作用。然而,mitoK(Ca)和mitoK(ATP)在西地那非诱导的心脏保护中的相对作用仍不清楚。在本研究中,成年雄性ICR小鼠在进行20分钟全心缺血(随后在Langendorff模式下再灌注30分钟)前24小时腹腔注射西地那非(0.71毫克/千克)进行预处理。在西地那非给药前30分钟或缺血前10分钟给予蜂毒素(K(Ca)阻滞剂)或5-羟基癸酸(5-HD;mitoK(ATP)阻滞剂)。西地那非治疗可减小梗死面积,而蜂毒素或5-HD均可消除这种作用。此外,在注射西地那非前48小时使用小干扰RNA(siRNA)对K(Ca)的β1亚基(K(Ca)-β1)进行体内基因敲低,可阻断西地那非的梗死限制作用。在用非靶向siRNA处理的小鼠中,西地那非的保护作用得以保留。蛋白质免疫印迹法显示K(Ca)-β1在心脏线粒体中有选择性蛋白表达,以及siRNA对K(Ca)-β1的基因敲低作用。西地那非治疗后K(Ca)-β1蛋白水平未上调。我们得出结论,mitoK(Ca)和mitoK(ATP)在触发和介导西地那非诱导的延迟心脏保护中均起关键作用。结果表明,mitoK(Ca)和mitoK(ATP) 的激活对于维持线粒体稳态以及减少西地那非诱导的缺血再灌注损伤预处理中的细胞死亡至关重要。